cogem.net

What cogem.net does

COGEM (Commissie Genetische Modificatie / Netherlands Commission on Genetic Modification) is an independent scientific advisory body of the Dutch government, established under the Environmental Management Act (Wet milieubeheer). It advises the Dutch government — primarily the Ministry of Infrastructure and Water Management (IenW) — on the risks of genetically modified organisms (GMOs) for humans and the environment, and signals ethical and societal aspects of genetic modification. The organization consists of approximately 40 members with expertise spanning ecology, virology, molecular biology, genetic modification, ethics, and philosophy, supported by a secretariat. Its statutory mandate requires a quadrennial external evaluation, with the most recent (2025) confirming its status as a top performer in its field nationally and in Europe.

COGEM's core outputs are advisory reports, commissioned research reports, pathogenicity classification lists for viruses and fungi, signaling letters on emerging ethical issues, and periodic trend analyses (jointly with the Health Council of the Netherlands). Its proprietary technical assets include the COGEM Formula (for calculating reduction of free lentiviral vector particles in gene therapy clinical studies) and generic environmental risk assessment frameworks that enable streamlined permit processing. Partnerships with CCMO, ZKBS (Germany), EFSA, and Bureau GGO extend its advisory influence into EU-level biotechnology regulation.

COGEM is not a commercial entity: it does not sell products or services and does not have investors or external ownership. Its activities are funded through the Dutch government under the Environmental Management Act. Distribution occurs via direct submission to ministries and Parliament, publication on the cogem.net website (~2,000 PDFs), a quarterly newsletter, and active social media presence on X.com, Bluesky, and LinkedIn. Recent thematic expansions include a July 2026 research call on genetically modified biostimulants and the November 2026 International Symposium on AI & Biotechnology.

Name

cogem.net

Legal name

Commissie Genetische Modificatie

Website

https://cogem.net

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

COGEM (Commissie Genetische Modificatie) is an independent Dutch government advisory body that advises ministers and Parliament on risks of genetically modified organisms and ethical-societal aspects of genetic modification, supported by ~40 expert members and a secretariat.

Ownership category

akta.pro rank

Product category

Government Scientific Advisory Services

NAICS

Administration of Environmental Quality Programs (9241), Regulation of Agricultural Marketing and Commodities (926140)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAJAEAN

Novel Foods, GMOs & Food Additives Approval

Healthcare & Life Sciences/Public Health, Government & Regulators/Food Safety & Nutrition Regulatory Authorities

SECONDARYAFALAHAH

GMO/Non-GMO & Bioengineered Disclosure Verification (label compliance support)

Agriculture & Food Production/Food Safety, Testing & Certification/Labeling, Nutrition & Allergen Verification Services

Keywords

• Scientific advisory services
• GMO risk assessment
• Biotechnology regulation
• Pathogenicity classification
• Genetic modification ethics

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels4 records

Core offering

COGEM is an independent scientific advisory body of the Dutch government that advises ministers and state secretaries on the safety of genetically modified organisms (GMOs) for humans and the environment, and signals ethical-societal aspects of genetic modification. Its outputs include advisory reports, commissioned research reports, pathogenicity classification lists, signaling letters, and periodic trend analyses on biotechnology.

Product overview

COGEM (Netherlands Commission on Genetic Modification) is an independent scientific advisory body of the Dutch government, not a commercial product company. Its services consist of advisory reports, commissioned research reports, pathogenicity classification lists, signaling letters, and trend analyses that advise the government on risks of genetically modified organisms for humans and environment, and ethical-societal aspects. The COGEM Formula is a specialized calculation methodology for viral vector risk assessment.

Differentiator

Problem solved

Functional benefit

Products and services

• Advisory Reports (Adviezen) Scientific advisory reports providing guidance to the Dutch government on risks of genetically modified organisms for humans and the environment, and ethical-societal aspects of genetic modification.
• Research Reports (Onderzoeksrapporten) Commissioned research reports investigating specific topics related to genetic modification, biotechnology, risk assessment, and environmental safety.
• Pathogenicity Classification Lists Classification lists of pathogenic and non-pathogenic microorganisms, fungi, DNA and RNA viruses used for regulatory risk assessment of genetically modified organisms.
• Signaling Letters (Signalerende brieven) Early warning and signaling documents highlighting emerging issues, ethical concerns, and societal aspects related to genetic modification and biotechnology.
• Trend Analysis Biotechnology Periodic trend analyses published jointly with the Health Council of the Netherlands, examining biotechnology developments and their implications for policy and regulation.
• COGEM Formula A mathematical formula for calculating the reduction ratio of free lentiviral or gammaretroviral vector particles after ex vivo transduction, used in environmental risk assessment for gene therapy clinical studies.

Quantifiable outcome

• COGEM issues advisory reports, research reports, classification lists, and signalling letters on GMO safety and ethical aspects, used by government ministries for regulatory decisions.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Central Committee on Research Involving Human Subjects (CCMO)coreStrategic or Co-development PartnerCOGEM and CCMO jointly commissioned research into the risk of unintended germline modification in gene therapy, published as a joint research report (CGM 2025-03). This collaboration addresses shared regulatory interest in the safety of new gene therapies.
• Health Council of the Netherlands (Gezondheidsraad)coreStrategic or Co-development PartnerCOGEM and the Health Council jointly publish the periodic Biotechnology Trend Analysis. Previous joint reports include 'Intervening in Human DNA' (2017) on germline modification. Both bodies provide advisory input to the Dutch government on biotechnology.
• German Commission on Biological Safety (ZKBS)coreStrategic or Co-development PartnerCOGEM and ZKBS issued a joint open letter to the European Commission on the environmental risk assessment of new vaccine developments based on samRNAs and VRPs. They share concerns about ensuring environmental safety guarantees in EC responses.
• Bureau GGOcoreOthersBureau GGO requests COGEM to provide advice on generic environmental risk assessments for clinical studies involving genetically modified organisms. Bureau GGO oversees GMO permit procedures in the Netherlands.
• Perseus BVminorImplementation/ SI/ Consulting PartnerCOGEM commissioned Perseus BV to conduct a literature study on the establishment and proliferation potential of cyanobacteria, to inform risk assessments for GM cyanobacteria permit applications.
• Bureau KLB ConsortiumminorImplementation/ SI/ Consulting PartnerAn external consortium led by Bureau KLB conducted research on biotechnology policy resilience, learning lessons from the COVID-19 pandemic for future vaccine and medicine development with GMOs, commissioned by COGEM.
• Scientific Council for Government Policy (WRR)minorStrategic or Co-development PartnerWRR provided support for the 2016 joint Trend Analysis Biotechnology publication by COGEM and the Health Council, contributing governmental policy expertise.
• European Food Safety Authority (EFSA)coreStrategic or Co-development PartnerCOGEM provides responses to EFSA draft guidance documents, such as the draft guidance on characterization and risk assessment of micro-organisms used in the food chain. COGEM also recommends its positions to EFSA for inclusion in their guidelines.

Scale indicators4 records

Recent moves6 records

Expansion highlights10 records

Direct peers

• Gezondheidsraad (Health Council of the Netherlands): The Dutch Health Council is an independent scientific advisory body to the Dutch government on health and biomedical topics, and a joint publisher of the periodic Biotechnology Trend Analysis with COGEM. It operates a structurally similar model in an adjacent domain.
• Bureau GGO: Bureau GGO is the Dutch permitting authority for GMO activities and routinely requests COGEM advice on generic environmental risk assessments. It is COGEM's primary commissioning counterpart within the Dutch regulatory system.
• Zentrale Kommission für die Biologische Sicherheit (ZKBS): Germany's Central Commission on Biological Safety is a statutory scientific advisory body that assesses GMO and biosafety risks for the German federal government. It is the closest international counterpart to COGEM, with whom it has issued joint positions to the European Commission.
• Haut Conseil des Biotechnologies (HCB): France's High Council on Biotechnology advises the French government on GMO and biotechnology issues, including environmental, health, and ethical dimensions. It is a structural peer to COGEM as another EU member-state GMO advisory body with a similar remit.
• Swiss Federal Ethics Committee on Non-Human Biotechnology (ECNH): Switzerland's ECNH advises on ethical issues of non-human biotechnology and genetic engineering, closely paralleling COGEM's ethical-and-societal signalling mandate alongside its technical risk assessment function.
• Advisory Committee on Releases to the Environment (ACRE): ACRE is the UK's independent statutory advisory committee providing scientific advice on the release and marketing of GMOs. Its mandate and function (independent risk advice to a national regulator) directly mirrors COGEM's role in the Netherlands.
• Swedish Gene Technology Advisory Board (Gentekniknämnden): Sweden's Gene Technology Advisory Board advises the Swedish government on GMO and gene technology matters. It is another small EU member-state GMO advisory body with a mandate and operating model directly comparable to COGEM's.
• Central Committee on Research Involving Human Subjects (CCMO): CCMO is the Dutch central committee overseeing research with human subjects, including gene therapy trials. It co-commissions research with COGEM (e.g., CGM 2025-03 on germline modification) and shares regulatory overlap in advanced therapy medicinal products.
• Belgian Biosafety Advisory Council (BAC): The Belgian Biosafety Advisory Council provides independent scientific advice on the contained use and deliberate release of GMOs and pathogens to the Belgian federal government. It performs the same national GMO advisory function as COGEM in a neighboring jurisdiction.

Broad incumbents

• EFSA GMO Panel: The European Food Safety Authority's GMO Panel provides EU-level scientific opinions on genetically modified food/feed and environmental risk assessment. It is the supranational body that consumes COGEM's inputs and shapes the rules COGEM implements nationally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/cogemnet
• LinkedInlinkedin.com/company/cogem

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cogem.net